Tibet Pharmaceuticals Announces Availability Of Third Quarter 2011 Earnings Call Transcript
Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty
pharmaceutical company engaged in the development, manufacturing and
marketing of traditional Tibetan medicine in China, today announced the
Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced the availability of the transcript for its third quarter 2011 earnings conference call, held on November 15th. During the conference call Sally He, Tibet Pharmaceutical’s VP and Assistant to the Chairman, translated Chairman Hong Yu’s comments into English by stating, “Despite rising raw material costs, Tibet Pharmaceuticals maintained relatively high levels of revenue, with $8.6 million reported in the third quarter, and $1.6 million in net income. We remain optimistic about the long-term prospects of the pharmaceuticals sector as we seek to establish ourselves as a leading manufacturer and distributor of Tibetan medicine in China.” During the conference call Tibet’s management team talked about the company’s portfolio of traditional Tibetan medicine products and full details surrounding its revenue and earnings numbers for the third quarter ended September 30, 2011. Interested parties are encouraged to read the full transcript of the conference call, which is available at: http://www.trilogy-capital.com/autoir/tbet_autoir.html. About Tibet Pharmaceuticals, Inc. Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ: TBET) is an emerging specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals’ products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company’s 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals. For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Research Report, Investor Portal and Overview Video. For more information on Tibet Pharmaceuticals, please visit: www.tibetpharmaceuticals.com. Forward-Looking Statements This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. Specifically, references herein to contemplated growth in company revenues and/or earnings or expected company valuations are forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, changes in company valuations and investor perceptions of companies, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In particular, the company advises investors that the company commissioned the research report discussed in this press release. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.